JP2020536892A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536892A5 JP2020536892A5 JP2020520112A JP2020520112A JP2020536892A5 JP 2020536892 A5 JP2020536892 A5 JP 2020536892A5 JP 2020520112 A JP2020520112 A JP 2020520112A JP 2020520112 A JP2020520112 A JP 2020520112A JP 2020536892 A5 JP2020536892 A5 JP 2020536892A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- activator
- composition according
- hours
- paddle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 239000012190 activator Substances 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 8
- 238000010828 elution Methods 0.000 claims 5
- 238000000338 in vitro Methods 0.000 claims 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 150000004677 hydrates Chemical class 0.000 claims 3
- 239000011159 matrix material Substances 0.000 claims 3
- RGPDIGOSVORSAK-STHHAXOLSA-N naloxone hydrochloride Chemical compound Cl.O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C RGPDIGOSVORSAK-STHHAXOLSA-N 0.000 claims 3
- 239000003402 opiate agonist Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims 2
- 239000003456 ion exchange resin Substances 0.000 claims 2
- 229920003303 ion-exchange polymer Polymers 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 229960004127 naloxone Drugs 0.000 claims 2
- 229960003086 naltrexone Drugs 0.000 claims 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 2
- 229940121367 non-opioid analgesics Drugs 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- ZFSXKSSWYSZPGQ-UHFFFAOYSA-N (2-hydroxycyclopentyl)azanium;chloride Chemical group Cl.NC1CCCC1O ZFSXKSSWYSZPGQ-UHFFFAOYSA-N 0.000 claims 1
- OJHZNMVJJKMFGX-BWCYBWMMSA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;(2r,3r)-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC OJHZNMVJJKMFGX-BWCYBWMMSA-N 0.000 claims 1
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 claims 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims 1
- BQNSLJQRJAJITR-UHFFFAOYSA-N 1,1,2-trichloro-1,2-difluoroethane Chemical compound FC(Cl)C(F)(Cl)Cl BQNSLJQRJAJITR-UHFFFAOYSA-N 0.000 claims 1
- DYUTXEVRMPFGTH-UHFFFAOYSA-N 4-(2,5-dimethylphenyl)-5-methyl-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C(=CC=C(C)C=2)C)=C1C DYUTXEVRMPFGTH-UHFFFAOYSA-N 0.000 claims 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 claims 1
- OZYUPQUCAUTOBP-QXAKKESOSA-N Levallorphan Chemical compound C([C@H]12)CCC[C@@]11CCN(CC=C)[C@@H]2CC2=CC=C(O)C=C21 OZYUPQUCAUTOBP-QXAKKESOSA-N 0.000 claims 1
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 claims 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 1
- 229960001736 buprenorphine Drugs 0.000 claims 1
- 229960004126 codeine Drugs 0.000 claims 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 1
- -1 cyclazacin Chemical compound 0.000 claims 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims 1
- 229960004242 dronabinol Drugs 0.000 claims 1
- 229960002428 fentanyl Drugs 0.000 claims 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims 1
- 229960000240 hydrocodone Drugs 0.000 claims 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims 1
- 229960001410 hydromorphone Drugs 0.000 claims 1
- 229960002738 hydromorphone hydrochloride Drugs 0.000 claims 1
- 229960000263 levallorphan Drugs 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 229960005297 nalmefene Drugs 0.000 claims 1
- 229960005250 naloxone hydrochloride Drugs 0.000 claims 1
- 229960000858 naltrexone hydrochloride Drugs 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 229960002085 oxycodone Drugs 0.000 claims 1
- 229960003617 oxycodone hydrochloride Drugs 0.000 claims 1
- 229960005118 oxymorphone Drugs 0.000 claims 1
- 229960005489 paracetamol Drugs 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 claims 1
- 229960005126 tapentadol Drugs 0.000 claims 1
- 229960004380 tramadol Drugs 0.000 claims 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023090883A JP2023123471A (ja) | 2017-10-09 | 2023-06-01 | 医薬レジネート組成物、それを作製する方法、およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762569813P | 2017-10-09 | 2017-10-09 | |
| US62/569,813 | 2017-10-09 | ||
| PCT/US2018/054830 WO2019074829A1 (en) | 2017-10-09 | 2018-10-08 | RESINATE-BASED PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEM |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023090883A Division JP2023123471A (ja) | 2017-10-09 | 2023-06-01 | 医薬レジネート組成物、それを作製する方法、およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020536892A JP2020536892A (ja) | 2020-12-17 |
| JP2020536892A5 true JP2020536892A5 (enExample) | 2021-11-18 |
Family
ID=66100936
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520112A Pending JP2020536892A (ja) | 2017-10-09 | 2018-10-08 | 医薬レジネート組成物、それを作製する方法、およびその使用 |
| JP2023090883A Pending JP2023123471A (ja) | 2017-10-09 | 2023-06-01 | 医薬レジネート組成物、それを作製する方法、およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023090883A Pending JP2023123471A (ja) | 2017-10-09 | 2023-06-01 | 医薬レジネート組成物、それを作製する方法、およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11690840B2 (enExample) |
| EP (1) | EP3694555A4 (enExample) |
| JP (2) | JP2020536892A (enExample) |
| CN (2) | CN111629758A (enExample) |
| AU (3) | AU2018347991A1 (enExample) |
| BR (1) | BR112020007061A2 (enExample) |
| CA (1) | CA3078844A1 (enExample) |
| IL (2) | IL273904B2 (enExample) |
| WO (1) | WO2019074829A1 (enExample) |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL53462A (en) | 1976-11-26 | 1980-12-31 | Pennwalt Corp | Prolonged release pharmaceutical preparations containing ion exchange drug complexes |
| US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
| US20030118641A1 (en) | 2000-07-27 | 2003-06-26 | Roxane Laboratories, Inc. | Abuse-resistant sustained-release opioid formulation |
| WO2001032148A1 (en) | 1999-10-29 | 2001-05-10 | Euro-Celtique, S.A. | Controlled release hydrocodone formulations |
| SI1299104T1 (sl) | 2000-02-08 | 2009-10-31 | Euro Celtique Sa | Oralne formulacije opioidnih agonistov, varne pred zlorabo |
| AR039744A1 (es) * | 2002-06-26 | 2005-03-09 | Alza Corp | Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada |
| US8343546B2 (en) | 2005-09-13 | 2013-01-01 | Coating Place, Inc. | Ion exchange resin treated to control swelling |
| EP2018160B1 (en) * | 2006-03-16 | 2011-12-14 | Tris Pharma, Inc. | Modified release formulations containing drug-ion exchange resin complexes |
| CA2689101C (en) | 2007-05-30 | 2013-01-22 | Neos Therapeutics, Lp | Modifying drug release in suspensions of ionic resin systems |
| JP5482012B2 (ja) * | 2008-09-19 | 2014-04-23 | セイコーエプソン株式会社 | ターゲット支持装置、ターゲット搬送機構及び液体噴射装置 |
| WO2011063164A2 (en) | 2009-11-18 | 2011-05-26 | Steady Sleep Rx Co., Inc. | Sustained release cannabinoid medicaments |
| WO2011107855A2 (en) | 2010-03-04 | 2011-09-09 | Torrent Pharmaceuticals Limited | Sustained release oral liquid suspension dosage form |
| US8623409B1 (en) * | 2010-10-20 | 2014-01-07 | Tris Pharma Inc. | Clonidine formulation |
| US20130230587A1 (en) * | 2010-11-10 | 2013-09-05 | Rubicon Research Private Limited | Sustained release compositions |
| EP2670400A1 (en) * | 2011-02-02 | 2013-12-11 | Alpharma Pharmaceuticals LLC | Pharmaceutical composition comprising opioid agonist and sequestered antagonist |
| WO2013003845A1 (en) | 2011-06-30 | 2013-01-03 | Neos Therapeutics, Lp | Abuse resistant drug forms |
| WO2013119231A1 (en) | 2012-02-09 | 2013-08-15 | Tris Pharma, Inc. | Abuse resistant opioid drug - ion exchange resin complexes having hybrid coatings |
| CA2852042C (en) | 2012-03-02 | 2018-05-01 | Rhodes Pharmaceuticals L.P. | Tamper resistant immediate release formulations |
| EP2968151B1 (en) * | 2013-03-13 | 2017-04-19 | Tris Pharma, Inc. | Benzonatate modified release solid tablets and capsules |
| MA41152A (fr) | 2014-12-12 | 2017-10-17 | Johnson & Johnson Consumer Inc | Procédé de fabrication de particules de résinate de phényléphrine ; particules de résinate de phényléphrine et utilisation des particules de résinate de phényléphrine dans des formulations pharmaceutiques |
| EP3522890A4 (en) * | 2016-10-10 | 2020-06-03 | Rhodes Pharmaceuticals L.P. | PHARMACEUTICAL RESINATE COMPOSITIONS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
-
2018
- 2018-10-08 CA CA3078844A patent/CA3078844A1/en active Pending
- 2018-10-08 IL IL273904A patent/IL273904B2/en unknown
- 2018-10-08 IL IL311303A patent/IL311303A/en unknown
- 2018-10-08 CN CN201880078034.9A patent/CN111629758A/zh active Pending
- 2018-10-08 AU AU2018347991A patent/AU2018347991A1/en not_active Abandoned
- 2018-10-08 BR BR112020007061-0A patent/BR112020007061A2/pt active Search and Examination
- 2018-10-08 EP EP18866039.3A patent/EP3694555A4/en active Pending
- 2018-10-08 JP JP2020520112A patent/JP2020536892A/ja active Pending
- 2018-10-08 US US16/754,940 patent/US11690840B2/en active Active
- 2018-10-08 WO PCT/US2018/054830 patent/WO2019074829A1/en not_active Ceased
- 2018-10-08 CN CN202410622045.6A patent/CN119524126A/zh active Pending
-
2022
- 2022-03-16 AU AU2022201848A patent/AU2022201848B2/en active Active
-
2023
- 2023-05-19 US US18/199,475 patent/US20230285388A1/en not_active Abandoned
- 2023-06-01 JP JP2023090883A patent/JP2023123471A/ja active Pending
-
2024
- 2024-09-05 AU AU2024219439A patent/AU2024219439A1/en active Pending
-
2025
- 2025-08-13 US US19/298,851 patent/US20250375438A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8987291B2 (en) | Opioid-containing oral pharmaceutical compositions and methods | |
| JP2015044834A5 (enExample) | ||
| AU2011271429B2 (en) | Sustained release composition comprising an amine as active agent and a salt of a cyclic organic acid | |
| RU2004106619A (ru) | Композиции опиоидного агониста, содержащие высвобождаемый и изолированный антагонист | |
| RU2000101024A (ru) | Опоидные анальгетики с контролируемым высвобождением активных веществ | |
| JP2005247859A5 (enExample) | ||
| JP2015511953A5 (enExample) | ||
| JP2014510094A5 (enExample) | ||
| HRP20120641T1 (hr) | Oralni farmaceutski oblici doziranja otporni na neovlašteno korištenje koji sadrže opioidni analgetik | |
| JP2018012711A5 (enExample) | ||
| CA2547334A1 (en) | Methods and compositions for deterring abuse of opioid containing dosage forms | |
| JP2011137020A5 (enExample) | ||
| HRP20150835T1 (hr) | Farmaceutski oblici doziranja s kontroliranim oslobađanjem | |
| JP2004515455A5 (enExample) | ||
| JP2015500273A5 (enExample) | ||
| HUP0000138A2 (hu) | Szabályozott hatóanyag-leadású opioid analgetikumokat tartalmazó gyógyászati készítmények | |
| JP2010511683A5 (enExample) | ||
| JP2016014040A5 (enExample) | ||
| ME00398B (me) | Oralne formulacije opijatnog agonista otporne na mehaničke, termičke i/ili hemijske promjene fizičkih osobina doznog oblika | |
| JP2011519930A5 (enExample) | ||
| WO2008045556A2 (en) | Novel synergistic opioid-cannabinoid codrug for pain management | |
| WO2020055725A4 (en) | Dopamine d3 receptor selective antagonists/partial agonists and uses thereof | |
| CN105120846A (zh) | 抗篡改的药物制剂 | |
| JP2014530185A5 (enExample) | ||
| JP2018080197A (ja) | オピオイド誘発性有害薬力学的応答を治療するためのシステムおよび方法 |